

If you are viewing this course as a recorded course after the live webinar, you can use the scroll bar at the bottom of the player window to pause and navigate the course.

This handout is for reference only. It may not include content identical to the powerpoint. Any links included in the handout are current at the time of the live webinar, but are subject to change and may not be current at a later date.

**ALS: A Clinical Population with Unique  
Communication Management and AAC Needs**

Part 1

**Hospital for  
Special Care**

*We Rebuild Lives.*

**Kim Winter, MA CCC-SLP  
September 15, 2016**

**Disclosure Statement**

- I received an honoraria from Speech Pathology.com to produce this presentation.
- I have no other financial or non-financial relationships to disclose.

8

## **Learner Outcomes**

- 1) describe the neurologic underpinnings of ALS
- 2) describe the differences between a compensation/management approach versus a treatment/remediation approach to SLP interventions
- 3) describe the Speech Staging System for ALS, the roles of the SLP and various interventions for each stage

9

## **ALS Epidemiology**

- Worldwide Incidence 0.86 to 2.4 per 100,000 per year  
(McGuire, V. & Nelson, L. M., 2006)
- US Incidence 2 per 100,000 per year
- Median survival rate is 3 years resulting in a prevalence rate of 6 per 100,000 per year.
- Onset typically occurs between 30-60 years of age
- Male to Female Ratio of 1.6:1

10

# NEUROANATOMY REVIEW

## What is ALS?

11

### **ALS = Amyotrophic Lateral Sclerosis**

Amyotrophic - means “without nourishment to muscles” and refers to the loss of signals nerve cells normally send to muscle cells.

Lateral - means “to the side” and refers to the location of the damage in the spinal cord.

Sclerosis - means “hardened” and refers to the hardened nature of the spinal cord in advanced ALS.

**\*\*Project ALS video**

<http://www.projectals.org/what-is-als>


12

# ALS

- Lou Gehrig's Disease
- Progressive
- Degenerative
- Upper and Lower Motor Neuron Disease
- Heterogeneous presentations
- No known cause
- No known cure

13


## Spectrum of Motor Neuron Diseases



14

## Review of Neuroanatomy

- UMN – neurons that have cell bodies in the brain and synapse on lower motor neurons.
- LMN – neurons that have cell bodies in the cranial nerve nuclei or the anterior horn of the spinal cord and synapse on muscle.



15

## Motor Neuron Damage

### Upper Motor Neurons

- Spasticity or Increased Tone
- Weakness (mild-moderate)
- Clumsiness or Loss of Dexterity
- Hyperreflexia
- Pathological Reflexes
- Pseudobulbar Affect (Emotional Lability)

### Lower Motor Neurons

- Weakness of Skeletal & Bulbar Muscles (moderate – severe)
- Hypotonia
- Hyporeflexia
- Fasciculations
- Muscle Atrophy or Wasting
- Cramps

16

## **Bulbar vs. Spinal Musculature**

### Bulbar Muscles

- Innervated by cranial nerves exiting from the brainstem
- Control speech and swallowing musculature

### Spinal Muscles

- Innervated by spinal nerves exiting the spinal cord
- Control limb, trunk and respiratory musculature

17

## **Bulbar-Onset ALS**

- Approximately 25% of all cases present with bulbar-onset form with dysarthria and dysphagia as the initial problem. (Murray, B. & Mitsumoto, H., 2006)
- The tongue is typically the first bulbar muscle to show signs of involvement.
- Faster progression of the disease than Spinal-Onset ALS.
- Bulbar onset is associated with shorter survival.

18

## **Spinal-Onset ALS**

- More common than bulbar-onset.
- Onset in limbs, trunk and muscles of respiration rather than bulbar musculature.
- Slower progression to bulbar musculature than Bulbar-Onset ALS progresses to limb musculature.
- Longer survival than bulbar-onset ALS.

19

## **Familial ALS**

- Familial or Inherited ALS = 10% of all diagnosed cases such that individuals have at least one affected family member. (Siddique, T. & Dellefave, L., 2006)
- Average age of onset is about a decade earlier than sporadic ALS. (Siddique, T. & Dellefave, L., 2006)
- Spinal onset is more likely than bulbar onset in Familial ALS.

20



## **Terminal Stage of ALS**

- Most patients with ALS die of progressive respiratory failure.
- The majority of patients with ALS die within 3-5 years of diagnosis.
- Respiratory status is an important predictor of survival duration.
- Palliative care and hospice care are usually involved in the pre-terminal and terminal stages of the disease progression.

21

## **Dysarthria and ALS**

- “25%-30% of ALS patients have dysarthria as a first or predominant sign in the early stage of the disease”. (Tomik, B. & Guilloff, R., 2010, p. 5)
- “On average, the diagnosis of ALS is made approximately 6 months after the appearance of initial symptoms”. (Ball, L., et al., 2002, p. 232)
- UMN and LMN decline results in a mixed (spastic and flaccid) dysarthria.
- Towards the end stages of the disease, flaccidity predominates.

22

## **Flaccid versus Spastic Dysarthria**

### Flaccid (LMN)

### Spastic (UMN)

Hypernasality	Imprecise consonants
Imprecise consonants	Monopitch
Breathiness	Reduced stress
Monopitch	Harshness
Nasal emission	Monoloudness
Audible inspiration	Low pitch
Harsh vocal quality	Slow rate
Short phrases	Hypernasality
Monoloudness	Strained-strangled voice
Lingual atrophy	Short phrases
Lingual fasciculations	Distorted vowels
(Darley, F., Aronson, A. & Brown, J., 23 1969, as cited in Duffy, J. ,2005)	

## **Mixed Dysarthria (UMN & LMN)**

Imprecise consonants	Prolonged phonemes
Hypernasality	Breathiness
Harshness	Audible inspiration
Slow rate	Nasal emission
Monopitch	Reduced stress
Short phrases	Prolonged intervals
Distorted vowels	Inappropriate silences
Low pitch	Strained-strangled voice
Monoloudness	Excess and equal stress
(Darley, F., Aronson, A. & Brown, J., 1969, as cited in Duffy, J. ,2005)	

24

## Compensation Not Remediation

“Although advances in understanding the pathophysiology of ALS have stimulated the development of new drug therapies, the mainstay of treatment for ALS patients remains symptomatic management.” (Miller, R.G. et al., 1999, p. 2)

“As with any incurable disease, the state of the art in treatment for ALS is symptom management (also referred to as ‘palliative care’).” (Mathy, P., n.d., para. 9)  
<http://www.asha.org/public/speech/disorders/ALSChallenge.htm>

25

## Compensation/Management versus Remediation/Treatment

### Remediation

Focus is on speech intelligibility.

Strengthening activities (i.e. oral motor exercises) and speech drills are utilized.

Compensatory strategies are gradually withdrawn as natural speech improves (restored function is the anticipated outcome).

Afflicted individual is the primary consideration.

### Compensation



Focus is on speech comprehensibility.

Energy conservation techniques are utilized.

There is an increased need for compensatory strategies to supplement natural speech with disease progression.

Recognition of communication variables.

26



### **Energy Conservation: Contraindications of Oral Motor Exercises and Speech Drills**

Lack of empirical evidence to support oral motor exercises (OMEs) in motor speech remediation.

“...the existing research literature provides insufficient evidence to support or refute the use of nonspeech OMEs”. (McCauley, R. et al., 2009, p. 353)

“At this time, based on theory and available evidence, the use of OMEs must be considered exploratory, and clients should be informed of this prior to initiating their use in treatment”. (McCauley, R. et al., 2009, p. 356)

29

### **Contraindications of Oral Motor Exercises and Speech Drills** *Continued*

Bandaaid on a gunshot wound approach – “Because of the pathophysiology and the degenerative nature of ALS, speech treatment strategies that are designed to increase strength or mobility of the oral musculature *are NOT recommended*”. (Ball, L. et. al., 2007, p.290)

Implications of “false hope”.

“...speech exercises emphasizing optimum performance can only prove to be a discouraging reminder of increasing loss of ability”. (Mathy, P., n.d., para. 11)

<http://www.asha.org/public/speech/disorders/ALSChallenge.htm>

Fatigues muscles using non-purposeful tasks.

Unclear if exercise to fatigue may actually hasten neurologic deterioration.

30

## **Is There a Role for Exercise?**

(Plowman, E. 2015)

- “...insufficient data to conclude that overuse weakness or functional decline actually occurs following exercise in PALS”. (p.1155)
- 18 exercise-based intervention studies reviewed (1960-2014)
  - “Limb and respiratory exercise, applied early and at mild to moderate intensities may have a positive impact for maintaining motor neuron integrity”. (p.1161)
  - “...recent data suggest that we need to consider the possible complementary role of mild forms of exercise...”. (p.1161)

31

## **Speech Staging System for ALS**

Stages:

- 1: No detectable speech disorder.
- 2: Obvious speech disorder with intelligible speech.
- 3: Reduction in speech intelligibility.
- 4: Natural speech supplemented with AAC
- 5: No useful natural speech.

(Yorkston, Beukelman, Strand & Bell (1999))

Additional Resource:

<http://aac-rerc.psu.edu/index.php/files/list/type/1>

32

## **What is the SLP's role at each stage?**

### **Stage 1: No detectable speech disorder.**

- Patient and family education regarding motor speech changes.
- Discussion regarding voice banking.

33

## **Voice Banking versus Message Banking: What's the Difference?**

- Voice Banking: creation of a synthesized version of human voice from a large number of recorded messages.
- Message Banking: digitally recorded words, phrases and/or sentences using natural voice, intonation and inflection.
  - Message Banking by Proxy
  - Legacy Messages/Story Banking

(Costello, J., 2014, Boston Children's Hospital Message Banking Examples from People with ALS)

34

## **Voice Banking/Message Banking Options**

### Voice Banking:

- Model Talker
- Acapela
- VocaliD

### Message Banking:

- [www.messsagebanking.com](http://www.messsagebanking.com)
- Creation of wav files

35

## **Stage 2: Obvious speech disorder with intelligible speech.**

- Discuss compensatory speech comprehensibility strategies.
- Emphasize the communication partners' role in communication.
- Discuss energy conservation with regard to speech.

36



### Stage 3: Reduction in speech intelligibility.

- Continue to encourage use of compensatory strategies, emphasizing need to utilize multiple strategies.
- Initiate AAC evaluation when speech rate is approximately 100-125 wpm.
- Equipment options:
  - Voice amplifier
  - Palatal lift

37

### Supplemented Speech Interventions

- **Alphabet Supplementation** – speaker indicates the first letter of each word as they say the word.
- **Benefits** –
  - Reduces speaking rate
  - Allows for increased processing time for the listener
- **Limitations** –
  - Speaker must be able to have adequate upper extremity functioning in order to point/select letters
  - Increases the physical and cognitive demands (speech and pointing).

38

## Supplemented Speech Interventions Continued

- **Topic Supplementation** – speaker indicates the topic of the message.
- Particularly useful when the speaker is changing topics of conversation.
- **Benefits** –  
Provides greater contextual support for the listener by constraining listener expectations for presented messages.
- **Limitations** –  
Research demonstrates that it is not as effective as alphabet supplementation.

39

## Supplemented Speech Interventions Continued

- **Gestural Supplementation** – gestures accompany or illustrate speech. This can also include pointing to environmental props (i.e. signs).
- **Benefits** –
- No additional equipment, portable, always available.
- **Limitations** –
- Idiosyncratic.
- Not all messages are “gesturable”.
- Impairments in upper extremity functioning are a limiting factor.

40

## **Supplemented Speech Interventions Summary**

- Overall, dysarthric speakers' speech comprehensibility improved when supplemented speech strategies were used.
- Alphabet supplementation and gestures yielded more significant results than topic cues.
- The greater the speech severity, the greater the benefits; however, also more variability in performance. (Hanson, E. et al., 2004)

41

## **Stage 3: Reduction in speech intelligibility.**

- Continue to encourage use of compensatory strategies, emphasizing the need to utilize speech supplementation strategies.
- Initiate AAC evaluation when speech rate is approximately 100-125 wpm.
- Equipment options:
  - Voice amplifier
  - Palatal lift

42


## Speech Intelligibility and Speaking Rate

- Speaking rate is an important predictor of speech intelligibility. (Yorkston, K., et al., 1993; Ball, L., et al., 2002; Ball, L., et al., 2005)
- Speaking rate tends to decline before reductions in intelligibility of speech are noted:
  - Is the reduced speaking rate a compensatory strategy (conscious or unconscious)?
  - Is it just an artifact of the patient's decline in neuro-motor functioning? (Ball, L., et al., 2002)

43

## Relationship Between Intelligibility & Speaking Rate

(Ball, L. et al., 2002, p.234)




44

## Perceived Effort and Speech Intelligibility


(Wilkinson, C. et al., 1995, p.142)

FIGURE 3. Hypothetical representation of changes in intelligibility and perceived effort as dysarthria associated with ALS progresses.



## Speech Deterioration: Intelligibility & # of Months Post-Diagnosis

(Ball, L. et al., 2002, p.233)



## **Timeliness of AAC Evaluations - “Reality Check”**

- Insurance denial issues.
- Early introduction of AAC and patient acceptance:  
“...early introduction can be a challenging process since it may be quite upsetting for the person who does not yet require AAC to face the reality that this will eventually be the case”. (Doyle, M. & Phillips, B. 2001, p. 169)

47

## **Stage 3: Reduction in speech intelligibility.**

- Continue to encourage use of compensatory strategies, emphasizing the need to utilize speech supplementation strategies.
- Initiate AAC evaluation when speech rate is approximately 100-125 wpm.
- Equipment options:
  - Voice amplifier
  - Palatal lift


48

## Voice Amplification

- **Benefits** –
  - Easy to use: no significant training needed
  - Inexpensive: prices range \$50-\$400
  - Portable
  - Supports use of natural speech
- **Limitations** -
  - Hypophonia is often not the only issue
  - Amplifies ALL aspects of the user's speech, including hoarseness, breathiness, hypernasality, strained/strangled voice, etc.

49

## Palatal Lifts



50

## **Palatal Lift Efficacy**

Esposito, Mitsumoto & Shanks (2000):

- 21 out of 25 (84%) demonstrated reduced hypernasality
- 19 (76%) had moderate benefits for 6 months.
- Patients indicated it was easier to speak with less effort.
- Once severe labial and lingual weakness were observed, palatal lift was no longer beneficial.

51

## **The “Reality” of Palatal Lifts**

- Fabrication of the prosthesis generally takes 3 sessions – impressions, palatal lift fabrication and fitting/training.
- Hypernasality is not the only issue.
- Progressive nature of ALS.
- Logistical constraints - viewed as “another appointment”.
- Community prosthodontist support – ? variable or limited

52



### **Who might be a good candidate for a palatal lift?**

Yorkston, Miller and Strand (2004) use the following guidelines:

- “Poor velopharyngeal function in the presence of relatively preserved lip and tongue movement
- Preserved ability to swallow saliva
- Adequate dentition to support the prosthesis
- A relatively slow progression of the disorder, suggesting that the person will continue to rely on natural speech as the primary mode of communication for at least several months”. (p. 43)

53

### **Stage 4: Natural speech supplemented with AAC**

- Continue to encourage use of compensatory strategies to supplement natural speech attempts.
- Procure SGD (Speech Generating Device) equipment and provide training.
- Respect patient desires to NOT use AAC.

54

## **Stage 5: No useful natural speech.**

- Ongoing support for AAC communication (low-tech and high-tech).
- May need to modify existing systems as physical abilities decline.

55

## **Useful Websites**

### **ALS Information**

ALS Association: <http://www.alsa.org/>

MDA Association – ALS Division:

<https://www.mda.org/disease/amyotrophic-lateral-sclerosis>

Northeast ALS Consortium (NEALS):

<http://www.alsconsortium.org/>

Project ALS: <http://www.projectals.org/>

ALS Untangled: <http://www.alsuntangled.com/index.html>

### **Patient/Caregiver Resources and Online Support Groups**

ALS Forums: <http://www.alsforums.com>

Patients Like Me - ALS/MND:

<http://www.patientslikeme.com/als/community>

56

## Take Home Points

If you have a patient with a confirmed or possible Neuromuscular Disease that you are not familiar with or are not sure how to manage, please consider contacting your local Neuromuscular Clinic (ALSA or MDA).

THANK YOU!!

Kim Winter: 860-827-1958 ext. 2035 [kwinter@hfsc.org](mailto:kwinter@hfsc.org)  
[www.hfsc.org](http://www.hfsc.org)

57

## References

- Ball, L., et al. (2002). Timing of speech deterioration in people with amyotrophic lateral sclerosis. *Journal of Medical Speech-Language Pathology*, 10, (4), 231-235.
- Ball, L., et al. (2005). Monitoring speaking rate by telephone for persons with amyotrophic lateral sclerosis. *Journal of Medical Speech-Language Pathology*, 13, (3), 233-240.
- Ball, L., Beukelman, D & Bardach, L. (2007). Amyotrophic lateral sclerosis. In Beukelman, et. Al. (Eds.). *Augmentative Communication Strategies for Adults with Acute or Chronic Medical Conditions* (pp. 287-316). Baltimore, MD: Paul H. Brookes Publishing Co.
- Carroll-Thomas, S. (1995). Communication changes and challenges in ALS/MND. *Journal of Speech-Language Pathology and Audiology*, 19, (4), 281-282.
- Costello, J. (2014). Boston Children's Hospital Message Banking Examples from People with ALS. Retrieved August 20, 2016 from <http://www.childrenshospital.org/~media/F670672FE0574861B827A98F8B2551F8.ashx>
- Doyle, M. & Phillips, B. (2001). Trends in augmentative and alternative communication use by individuals with amyotrophic lateral sclerosis. *Augmentative and Alternative Communication*, (17), 167-178.
- Duffy, J. R. (2005). *Motor speech disorders: Substrates, differential diagnosis and management* (2<sup>nd</sup> Edition). Elsevier-Mosby.

58

## References

- Esposito, S., et al. (2000). Use of palatal lift and palatal augmentation prostheses to improve dysarthria in patients with amyotrophic lateral sclerosis: A case series. *The Journal of Prosthetic Dentistry*, 83, 90-98.
- Hanson, E. et al., (2004). Speech supplementation techniques for dysarthria: A systematic review. *Journal of Speech-Language Pathology*, 12 (2), p. ix-xxix.
- Mathy, P. (n.d.). Amyotrophic lateral sclerosis: A challenge for speech-language pathology. In *American Speech-Language Hearing Association*. Retrieved September 12, 2010 from <http://www.asha.org/public/speech/disorders/ALSChallenge.htm>
- McCauley, R. , et al. (2009). Evidence-based systematic review: Effects of nonspeech oral motor exercises on speech. *American Journal of Speech-Language Pathology*, 18 (4), 343-360.
- McGuire, V. & Nelson, L. M. (2006). Epidemiology in ALS. In Mitsumoto, et al. (Eds.). *Amyotrophic Lateral Sclerosis* (pp. 17-41). New York, NY: Taylor & Francis Group.
- Miller, R. G., et al. (1999). Practice parameter: The care of the patient with amyotrophic lateral sclerosis (An evidence-based review): Report of the Quality Standards Subcommittee on the American Academy of Neurology, *Neurology*, 52, 1311. Retrieved June 15, 2009, from <http://www.neurology.org/cgi/content/full/52/7/1311>

59

## References

- Murray , B & Mitsumoto, H. (2006). The spectrum of motor neuron disorders. In Brown, R.H., Swash, M., & Pasinelli, P. (Eds.). *Amyotrophic Lateral Sclerosis (2<sup>nd</sup> ed.)* (pp. 3-24). Boca Raton, FL: Taylor & Francis.
- Plowman, E. (2015). Is there a role for exercise in the management of bulbar dysfunction in Amyotrophic Lateral Sclerosis?. *Journal of Speech, Language, and Hearing Research*, 58, 1151-1166.
- Siddique, T. & Dellefave, L. (2006). Familial ALS and genetic approaches to ALS. In Mitsumoto, et. al. (Eds.). *Amyotrophic Lateral Sclerosis* (pp. 141-166). New York, NY: Taylor & Francis Group.
- Tomik, B. & Guilloff, R. (2010). Dysarthria in amyotrophic lateral sclerosis: A review. *Amyotrophic Lateral Sclerosis*, 11, 4-15.
- Wilkinson, C. et al. (1995). Features of spontaneous language in speakers with amyotrophic lateral sclerosis and dysarthria. *American Journal of Speech-Language Pathology*, 4, 139-142.

60

## References

- Yorkston, K. et al. (1993). Speech deterioration in amyotrophic lateral sclerosis: Implications for the timing of intervention. *Journal of Medical Speech-Language Pathology*, 1, (1), 35-46.
- Yorkston, K., Strand, E. & Kennedy, M. (1996). Comprehensibility of dysarthric speech: Implications for assessment and treatment planning. *American Journal of Speech-Language Pathology*, 5 (1), 55-66.
- Yorkston, K., Beukelman, D., Strand, E., & Bell, K. (1999). *Management of motor speech disorders in children and adults*. Austin, TX: PRO-ED. \*\*\*ALS Speech Staging; from 2ndary source\*\*\*\*
- Yorkston, K., Miller, R., & Strand, E. (2004). *Management of speech and swallowing in degenerative diseases (2<sup>nd</sup> Edition)*. Austin, TX: PRO-ED.

61